Document Detail


The timing of intra-coronary infusion of G-CSF mobilized peripheral blood stem cells influences cardiac function and in-stent restenosis in patients with myocardial infarction.
MedLine Citation:
PMID:  19203805     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We hypothesized that delaying the timing of intra-coronary infusion of G-CSF mobilized stem cell until at least 4 weeks after coronary stenting should avoid the stimulation of vascular smooth muscle cells during the early active cellular proliferative phase, thus decreases in-stent restenosis while preserving the beneficial effect of stem cell therapy on cardiac function in patients with myocardial infarction (MI). 25 patients with ST-elevation myocardial infarction (STEMI) treated with stenting were enrolled in this pilot study. The ages of MI at the time of cell treatment were from 1 month to 59 months. At 6 months follow-up, the left ventricular ejection fraction (LVEF) increased from 32% to 37.7% and the stress thallium perfusion defect decreased from 31.4% to 28.1%. Cell treatment-related complications such as arrhythmias were not observed. 9 patients who underwent cell treatment less than 3 months after coronary stenting were evaluated for in-stent restenosis; it was found in only 1 patient. This pilot study shows that delayed more than 4 weeks after coronary stenting but less than 3 months after MI, intra-coronary infusion of G-CSF mobilized PBSCs may improve cardiac function without triggering in-stent restenosis.
Authors:
Kyung-Soo Kim; Jiyong Jin; Young-Yiul Lee; Sung-Il Choi; Jin-Ho Shin; Jeong-Hyun Kim; Heon-Gil Lim; Bang-Hun Lee; Yun-Young Choi; Seok-Mo Lee; Hyun-Chul Koh
Related Documents :
2002685 - Early outcome after placement of a metallic intracoronary stent: initial mayo clinic ex...
22131585 - Repeated pericardiocentesis as palliative treatment for tamponade associated with cardi...
10751765 - Angiographic and clinical outcome of a new self-expanding intracoronary stent (radius):...
20129545 - 3-year clinical follow-up of the xience v everolimus-eluting coronary stent system in t...
15157565 - The role and assessment of ventricular peptides in heart failure.
2140315 - "silent" myocardial ischaemia in essential hypertension.
Publication Detail:
Type:  Clinical Trial; Letter; Research Support, Non-U.S. Gov't     Date:  2009-02-08
Journal Detail:
Title:  International journal of cardiology     Volume:  143     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-12-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  202-5     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Child, Preschool
Coronary Restenosis / therapy*
Drug Administration Schedule
Female
Granulocyte Colony-Stimulating Factor / administration & dosage*
Hematopoietic Stem Cell Mobilization / methods*
Humans
Infant
Infant, Newborn
Male
Myocardial Infarction / therapy*
Stents / adverse effects
Ventricular Function, Left / physiology*
Chemical
Reg. No./Substance:
143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Very rare minor homozygous GG genotype of tissue factor +5466A>G mutation in a patient with two cryp...
Next Document:  Stent fracture and restenosis after zotarolimus-eluting stent implantation.